IBDEI17J ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21606,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,21606,1,5,0)
 ;;=5^ALL, In Remission
 ;;^UTILITY(U,$J,358.3,21606,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,21607,0)
 ;;=204.10^^133^1317^46
 ;;^UTILITY(U,$J,358.3,21607,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21607,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,21607,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,21607,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,21608,0)
 ;;=204.11^^133^1317^47
 ;;^UTILITY(U,$J,358.3,21608,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21608,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,21608,1,5,0)
 ;;=5^CLL, In Remission
 ;;^UTILITY(U,$J,358.3,21608,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,21609,0)
 ;;=202.41^^133^1317^74
 ;;^UTILITY(U,$J,358.3,21609,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21609,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,21609,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,21609,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,21610,0)
 ;;=201.90^^133^1317^81
 ;;^UTILITY(U,$J,358.3,21610,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21610,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,21610,1,5,0)
 ;;=5^Hodgkin's Lymphoma, Unpsec Type & Site
 ;;^UTILITY(U,$J,358.3,21610,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,21611,0)
 ;;=785.6^^133^1317^87
 ;;^UTILITY(U,$J,358.3,21611,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21611,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,21611,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,21611,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,21612,0)
 ;;=200.20^^133^1317^90
 ;;^UTILITY(U,$J,358.3,21612,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21612,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,21612,1,5,0)
 ;;=5^Lymphoma,Burkitt's,Site Unspec
 ;;^UTILITY(U,$J,358.3,21612,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,21613,0)
 ;;=202.00^^133^1317^89
 ;;^UTILITY(U,$J,358.3,21613,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21613,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,21613,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Site Unspec
 ;;^UTILITY(U,$J,358.3,21613,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,21614,0)
 ;;=200.10^^133^1317^88
 ;;^UTILITY(U,$J,358.3,21614,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21614,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,21614,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Site Unspec
 ;;^UTILITY(U,$J,358.3,21614,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,21615,0)
 ;;=273.3^^133^1317^91
 ;;^UTILITY(U,$J,358.3,21615,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21615,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,21615,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,21615,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,21616,0)
 ;;=203.00^^133^1317^104
 ;;^UTILITY(U,$J,358.3,21616,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21616,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,21616,1,5,0)
 ;;=5^Multiple Myeloma w/o Rem
 ;;^UTILITY(U,$J,358.3,21616,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,21617,0)
 ;;=203.01^^133^1317^103
 ;;^UTILITY(U,$J,358.3,21617,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21617,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,21617,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,21617,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,21618,0)
 ;;=238.6^^133^1317^106
 ;;^UTILITY(U,$J,358.3,21618,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21618,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,21618,1,5,0)
 ;;=5^Plasmacytoma NOS
 ;;^UTILITY(U,$J,358.3,21618,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,21619,0)
 ;;=205.00^^133^1317^4
 ;;^UTILITY(U,$J,358.3,21619,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,21619,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,21619,1,5,0)
 ;;=5^AML w/o Remission
